TNF-alpha immunoconjugate therapy for the treatment of brain tumors
US11872288B2 · kind B2 · utility
1Cited by
0References
16Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 24, 2021 |
| Grant date | Jan 16, 2024 |
| Priority date | — |
| Expiry date | May 24, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to immunoconjugates, compositions, methods and uses for treating brain tumors, especially glioma, by administration of a tumour necrosis factor alpha (TNFα) immunoconjugate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.